Any condition which in the investigator’s opinion makes the patient unsuitable for study participation. 11. Requires therapeutic anticoagulation with warfarin at baseline; patients must be off warfarin or warfarin-derivative anti-coagulants at least 7 days prior to starting st udy drug; however, therapeutic or prophylactic therapy with low-molecular weight heparin is allowed. 12. Has history of known coagulopathy that increases the risk of bleeding or a history of clinically significant hemorrhage within 12 months of start of study drug. 13. Has evidence of intratumoral or peritumoral hemorrhage on baseline MRI scan other than those that are ≤ Grade 1 and either post-operative or stable on at least 2 consecutive MRI scans. 14. Has gastrointestinal bleeding or any other hemorrhage/bleeding event National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) > Grade 3 within 6 months of start of study drug. 3.6.